New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 12, 2013
05:55 EDTADUS, ADUS, ATRS, ATRS, BGMD, BGMD, DSCO, DSCO, EXPR, EXPR, GSOL, GSOL, KOPN, KOPN, PERI, PERI, SNSS, SNSSCompanies reporting Before the Market Open on Wednesday, March 13
Notable companies reporting before the opening bell on Wednesday include Addus Homecare (ADUS), Antares Pharma (ATRS), BG Medicine (BGMD), Discovery Laboratories (DSCO), Express (EXPR), Global Sources (GSOL), Kopin (KOPN), Perion Network (PERI), and Sunesis Pharmaceuticals (SNSS).
Sign up for a free trial to see the rest of the stories you've been missing.
November 19, 2014
07:05 EDTSNSSSunesis publishes vosaroxin Phase 1b/2 AML trial results
Subscribe for More Information
November 18, 2014
12:07 EDTADUSAddus HomeCare management to meet with Sidoti
Subscribe for More Information
10:32 EDTATRSAntares Pharma management to meet with Guggenheim
Subscribe for More Information
07:37 EDTSNSSStifel to hold a conference
Subscribe for More Information
07:02 EDTATRSAntares Pharma names James Fickenscher as SVP, CFO
Subscribe for More Information
November 17, 2014
11:56 EDTSNSSSunesis jumps after announcing plans to present data from VALOR trial
Subscribe for More Information
November 14, 2014
16:24 EDTSNSSBiotechnology Value Fund reports 5.1% passive stake in Sunesis
07:14 EDTATRSAmerican College of Rheumatology is holding a meeting
2014 ACR/ARHP Annual Meeting is being held in Boston on November 14-19.
November 13, 2014
10:57 EDTBGMDBG Medicine downgraded to Neutral from Buy at Ladenburg
Ladenburg downgraded BG Medicine to Neutral citing valuation following the company's Q3 results.
06:33 EDTBGMDBG Medicine sees 2014 revenue $2.8M-$3.0M, one estimate $3.10M
Subscribe for More Information
06:32 EDTBGMDBG Medicine reports Q3 EPS (7c), one estimate (7c)
Reports Q3 revenue $695K, one estimate $800.00K.
November 10, 2014
09:20 EDTSNSSOn The Fly: Pre-market Movers
Subscribe for More Information
07:13 EDTSNSSSunesis reports Q3 EPS (25c), consensus (17c)
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use